Printer Friendly

Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period.

Initiation of contraception during the postpartum period is important to prevent unintended pregnancy and short birth intervals, which can lead to negative health outcomes for mother and infant (1). In 2010, CDC published U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 (US MEC), providing evidence-based guidance for choosing a contraceptive method based on the relative safety of contraceptive methods for women with certain characteristics or medical conditions, including women who are postpartum (2). Recently, CDC assessed evidence regarding the safety of combined hormonal contraceptive use during the postpartum period. This report summarizes that assessment and the resulting updated guidance. These updated recommendations state that postpartum women should not use combined hormonal contraceptives during the first 21 days after delivery because of the high risk for venous thromboembolism (VTE) during this period. During 21-42 days postpartum, women without risk factors for VTE generally can initiate combined hormonal contraceptives, but women with risk factors for VTE (e.g., previous VTE or recent cesarean delivery) generally should not use these methods. After 42 days postpartum, no restrictions on the use of combined hormonal contraceptives based on postpartum status apply.

Importance of Contraception During the Postpartum Period

Half of all pregnancies in the United States are unintended, and these pregnancies have been associated with adverse pregnancy behaviors and outcomes, including later entry into prenatal care, decreased likelihood of smoking cessation, increased incidence of low birth weight, and decreased breastfeeding (3). In addition, short interpregnancy intervals can lead to negative consequences such as low birth weight and preterm birth (4). The postpartum period is an important time to initiate contraception because women are accessing the health-care system and might have increased motivation to avoid another pregnancy. Ovulation can occur as early as 25 days postpartum among nonbreastfeeding women, underscoring the importance of initiating contraception in the very early postpartum period (5).

However, safety of contraceptive use among postpartum women also must be considered. Hematologic changes that occur normally during pregnancy, including an increase in coagulation factors and fibrinogen and a decrease in natural anticoagulants, result in an increased risk for VTE during the postpartum period. In addition, many postpartum women have additional risk factors that further increase their risk for VTE, such as age [greater than or equal to]35 years, smoking, or recent cesarean delivery. This is of concern when considering postpartum contraception options because combined hormonal contraceptives (i.e., those that contain both estrogen and progestin) are themselves associated with a small increased risk for VTE among healthy women of reproductive age (6).

Rationale and Methods

US MEC, first published by CDC in 2010, was adapted from Medical Eligibility Criteria for Contraceptive Use, published by the World Health Organization (WHO) (2), which has been publishing global evidence-based contraceptive guidance since 1996. Although CDC adapted a small number of WHO recommendations and added a few new recommendations for U.S. health-care providers, the majority of the recommendations in the WHO guidance and US MEC are the same. Recommendations are provided using categories "1" to "4," based on the balance of benefits and harms signifying whether or not the contraceptive method is safe for use among women with a particular medical condition or characteristic; category 1 represents a method that is safe to use without restriction and category 4 represents an unacceptable health risk (Table 1). CDC is committed to ensuring that these recommendations remain up-to-date and based on the best available scientific evidence. An update can be triggered either by identification of new evidence or by any evidence-based updates made to the WHO global guidance.

In 2010, based on new evidence (7), WHO updated its guidance on the safety of combined hormonal contraceptives among postpartum nonbreastfeeding women to be more restrictive regarding the use of combined hormonal contraceptives during the first 42 days postpartum, particularly among women with other risk factors for VTE (6). Recommendations for breastfeeding women were not changed. Because of this WHO update, CDC initiated a process to assess whether its guidance similarly should be updated. Before this process, US MEC recommended that women less than 21 days postpartum generally should not use combined hormonal contraceptives, but that after that time, combined hormonal contraceptives could be used without restriction.

From a systematic review conducted by WHO and CDC and used in the consultation to update the WHO guidance, evidence from 13 studies showed that the risk for VTE among women within the first 42 days postpartum is 22-fold to 84-fold greater than the risk among nonpregnant, nonpostpartum reproductive age women (7). The risk is highest immediately after delivery, declining rapidly during the first 21 days, but not returning to baseline until 42 days postpartum in most studies. Use of combined hormonal contraceptives, which can cause a small increased risk for VTE in healthy reproductive age women, might theoretically pose an additional risk if used during this time. However, no evidence was identified regarding risk for VTE among postpartum women using combined hormonal contraceptives. The evidence also is limited by the small number of studies that report risk for VTE at precise intervals during the postpartum period and report baseline risk for VTE in a reference population for comparison with the risk among postpartum women. Evidence also was examined regarding the return to fertility among nonbreastfeeding postpartum women and indicated that ovulation can occur as early as 25 days postpartum, although fertile ovulation likely will not occur until at least 42 days postpartum (5).

As part of the CDC assessment, CDC recruited 13 persons from outside the agency to serve as ad hoc reviewers of the WHO revised recommendations; they were selected based on their expertise in thromboembolic disease, hematology, and family planning. The reviewers were asked to participate in a January 2011 teleconference with CDC, during which participants would review the evidence base and assess whether WHO's revised recommendations were suitable for use in the United States. A key issue identified was that immediate postpartum use of combined hormonal contraceptives would impose a high risk for VTE without any substantial benefit in pregnancy prevention because most nonlactating women will not have a fertile ovulation until at least 42 days postpartum (5). Women with risk factors for VTE in addition to being postpartum (e.g., obesity or cesarean delivery) are already at elevated risk for VTE; use of combined hormonal contraceptives theoretically would further compound that risk. Finally, access to contraceptive methods was a concern of the group; however, unlike methods that require a visit to a provider (e.g., implants and intrauterine devices [IUDs]), combined hormonal contraceptives can be started by the woman herself at the appropriate time if given a prescription or sample in advance (either before hospital discharge or at a postpartum visit).

Recommendations for Use of Combined Hormonal Contraceptives During the Postpartum Period

CDC recommends the following updated guidelines for the safety of combined hormonal contraceptives in postpartum women who are not breastfeeding (Table 1). In women who are <21 days postpartum, use of combined hormonal contraceptives represents an unacceptable health risk and should not be used (category 4). In women who are 21-42 days postpartum and have other risk factors for VTE in addition to being postpartum, the risks for combined hormonal contraceptives usually outweigh the advantages and therefore combined hormonal contraceptives generally should not be used (category 3); however, in the absence of other risk factors for VTE, the advantages of combined hormonal contraceptives generally outweigh the risks, and they can usually be used (category 2). In women who are >42 days postpartum, no restriction applies for the use of combined hormonal contraceptives because of postpartum status (category 1). Nonetheless, any other medical conditions still should be taken into consideration when determining the safety of the contraceptive method.

Separate recommendations in the 2010 US MEC for combined hormonal contraceptive use among women who are breastfeeding remain unchanged (2). These recommendations are based on evidence regarding potential negative effects of hormonal contraceptive use on breastfeeding, such as decreased duration of breastfeeding and higher rates of supplemental feeding (8). Among women who are breastfeeding and are <1 month postpartum, combined hormonal contraceptives are given a category 3 because of concerns about the effects of estrogen on breastfeeding duration and success. After 1 month, combined hormonal contraceptive use is given a category 2 for breastfeeding women. However, some of the updated recommendations based on risk for VTE in postpartum women now supersede the breastfeeding recommendations. For example, combined hormonal contraception is now classified as a category 4 (unacceptable health risk) for all postpartum women, regardless of breastfeeding status, for the first 21 days (Table 2).

Health-care providers assessing a woman's individual risk also should consider any other characteristics or medical conditions that might impact the classification. For postpartum women, this might include examining the recommendations for other risk factors for VTE, such as known thrombogenic mutations (category 4) or history of VTE with risk factors for recurrence (category 4), both of which pose an unacceptable health risk for combined hormonal contraceptive use, whether or not women are postpartum (2).

Recommendations for Use of Other Contraceptive Methods During the Postpartum Period

Recommendations for use of other contraceptives, including progestin-only hormonal contraceptives, remain unchanged and many are good options for postpartum women (Table 3). Progestin-only hormonal methods, including progestin-only pills, depot medroxyprogesterone acetate injections, and implants, are safe for postpartum women, including women who are breastfeeding, and can be initiated immediately postpartum (categories 1 and 2). IUDs, including the levonorgestrel-releasing IUD and copper-bearing IUD, also can be inserted postpartum, including immediately after delivery (categories 1 and 2) and are not associated with an increase in complications. Although IUD expulsion rates are somewhat higher when insertion occurs within 28 days of delivery, continuation rates at 6 months are similar among women who receive an IUD postpartum and those who plan for delayed insertion (9,10). Condoms can be used anytime (category 1), and the diaphragm and cap should be started at 6 weeks postpartum (category 1 after 6 weeks). In addition, women who have completed their childbearing might wish to consider sterilization at this time. Postpartum contraception is important for the health of mother and infant, and education for both health-care providers and women should focus on the range of contraception options and the safety of most of these methods during the postpartum period.

Acknowledgments

Ad hoc reviewers: David Eisenberg, MD, Washington Univ and Planned Parenthood of the St. Louis Region and Southwest Missouri, St. Louis, Missouri. Alisa Goldberg, MD, Brigham and Women's Hospital, Boston, Massachusetts. Michael Policar, MD, Univ of California, San Francisco; Emily Jackson, MD, Los Angeles, California. Andra James, MD, Duke Univ, Durham, North Carolina. Andrew Kaunitz, MD, Univ of Florida, Jacksonville, Florida. Barbara Konkle, MD, Puget Sound Blood Center, Seattle, Washington. Hal Lawrence, MD, Mary Mitchell, American College of Obstetricians and Gynecologists, Washington, DC. Charles Lockwood, MD, Yale Univ, New Haven, Connecticut. Susan Moskosky, MS, US Dept of Health and Human Svcs, Rockville, Maryland. Deborah Nucatola, MD, Planned Parenthood Federation of America, New York; Carolyn Westhoff, MD, Columbia Univ, New York, New York. Additional reviewers: Emily Godfrey, MD, Herbert Peterson, MD, Univ of North Carolina, Chapel Hill, North Carolina. Maria Steenland, MPH, National Center for Chronic Disease Prevention and Health Promotion, CDC.

References

(1.) CDC. Contraceptive use among postpartum women--12 states and New York City, 2004-2006. MMWR 2009;58:821-6.

(2.) CDC. U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edition. MMWR 2010;59(No. RR-4).

(3.) Gipson JD, Koenig MA, Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Family Plann 2008;39:18-38.

(4.) Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. Int J Gynecol Obstet 2005;89(Suppl 1):S25-33.

(5.) Jackson E, Glasier A. Return of ovulation and menses in postpartum, nonlactating women: a systematic review. Obstet Gynecol 2011;117:657-62.

(6.) World Health Organization. Combined hormonal contraceptive use during the postpartum period. Geneva, Switzerland: World Health Organization; 2010. Available at http://www.who.int/reproductivehealth/publications/family_planning/ rhr_10_15/en/ index.html. Accessed June 30, 2011.

(7.) Jackson E, Curtis K, Gaffield M. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 2011;117:691-703.

(8.) Kapp N, Curtis KM. Combined oral contraceptive use among breastfeeding women: a systematic review. Contraception 2010;82:10-6.

(9.) Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception 2009;80:327-36.

(10.) Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010;116:1079-87.

Reported by

Naomi K. Tepper, MD, Kathryn M. Curtis, PhD, Denise J. Jamieson, MD, Polly A. Marchbanks, PhD, Div of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. Corresponding contributor: Naomi K. Tepper, ntepper@cdc.gov, 770-488-6506.
TABLE 1. Updated recommendations for combined hormonal
contraceptives, including combined oral contraceptives, combined
hormonal patch, and combined vaginal ring, during the postpartum
period among nonbreastfeeding women

Condition                          Category *   Clarifications/Evidence

Postpartum
(nonbreastfeeding women)

a. <21 days                        4            Evidence: There is no
                                                direct evidence
                                                examining the risk for
                                                VTE among postpartum
                                                women using CHCs. VTE
                                                risk is elevated during
                                                pregnancy and
                                                postpartum; this risk
                                                is most pronounced in
                                                the first weeks after
                                                delivery, declining to
                                                near baseline levels by
                                                42 days postpartum. Use
                                                of CHCs, which
                                                increases the risk for
                                                VTE in healthy
                                                reproductive age women,
                                                might pose an
                                                additional risk if used
                                                during this time. Risk
                                                for pregnancy during
                                                the first 21 days
                                                postpartum is very low,
                                                but increases after
                                                that point; ovulation
                                                before first menses is
                                                common.

b. 21-42 days
   i. With other risk              3            Clarification: For
      factors for VTE (such as                  women with other risk
      age >35 years, previous                   factors for VTE, these
      VTE, thrombophilia,                       risk factors might
      immobility, transfusion                   increase the
      at delivery, BMI >30,                     classification to a
      postpartumhemorrhage,                     "4"; for example,
      postcesarean delivery,                    smoking, deep venous
      preeclampsia, or smoking)                 thrombosis/pulmonary
                                                embolism, known
  ii. Without other risk           2            thrombogenic mutations,
      factors for VTE                           and peripartum
                                                cardiomyopathy.
                                                Evidence: There is no
                                                direct evidence
                                                examining the risk for
                                                VTE among postpartum
                                                women using CHCs. VTE
                                                risk is elevated during
                                                pregnancy and
                                                postpartum; this risk
                                                is most pronounced in
                                                the first weeks after
                                                delivery, declining to
                                                near baseline levels by
                                                42 days postpartum. Use
                                                of CHCs, which
                                                increases the risk for
                                                VTE in healthy
                                                reproductive age women,
                                                might pose an
                                                additional risk if used
                                                during this time.
c. >42 days                        1

Abbreviations: VTE = venous thromboembolism; CHC = combined
hormonal contraceptive; BMI = body mass index (weight [kg]/height
[[m.sup.2]]).

* Categories: 1 = a condition for which there is no restriction for
the use of the contraceptive method, 2 = a condition for which the
advantages of using the method generally outweigh the theoretical
or proven risks, 3 = a condition for which the theoretical or
proven risks usually outweigh the advantages of using the method, 4
= a condition that represents an unacceptable health risk if the
contraceptive method is used.

TABLE 2. Updated recommendations for combined hormonal
contraceptives, including combined oral contraceptives, combined
hormonal patch, and combined vaginal ring, during the postpartum
period among breastfeeding women

Condition                            Category *

Postpartum
(breastfeeding women ([dagger]))

a. <21 days                          4

b. 21 to <30 days
   i. With other risk factors        3
      for VTE (such as age
      [greater than or equal to]
      35 years, previous VTE,
      thrombophilia, immobility,
      transfusion at delivery,
      BMI [greater than or equal
      to] 30, postpartum
      hemorrhage, postcesarean
      delivery, preeclampsia, or
      smoking)

  ii. Without other risk             3
      factors for VTE

c. 30-42 days
   i. With other risk factors        3
      for VTE (such as age
      [greater than or equal to]
      35 years, previous VTE,
      thrombophilia, immobility,
      transfusion at delivery,
      BMI [greater than or equal
      to] 30, postpartum
      hemorrhage, postcesarean
      delivery, preeclampsia, or
      smoking)

  ii. Without other risk             2
      factors for VTE

d. >42 days                          2

Condition                            Clarifications/Evidence

Postpartum                           Clarification: The U.S.
(breastfeeding women ([dagger]))     Department of Health and Human
                                     Services recommends that infants
                                     should be exclusively breastfed
                                     during the first 4-6 months of
                                     life, preferably for a full 6
                                     months. Ideally, breastfeeding
                                     should continue through the first
                                     year of life.

                                     Evidence: Clinical studies
                                     demonstrate conflicting results
                                     about effects on milk volume in
                                     women exposed to COCs during
                                     lactation; no consistent effect
                                     on infant weight has been
                                     reported. Adverse health outcomes
                                     or manifestations of exogenous
                                     estrogen in infants exposed to
                                     CHCs through breast milk have not
                                     been demonstrated. In general,
                                     these studies are of poor
                                     quality, lack standard
                                     definitions of breastfeeding or
                                     outcome measures, and have not
                                     included premature or ill
                                     infants. Theoretical concerns
                                     about effects of CHCs on breast
                                     milk production are greater in
                                     the early postpartum period when
                                     milk flow is being established.

a. <21 days                          Evidence: There is no direct
                                     evidence examining the risk for
                                     VTE among postpartum women using
                                     CHCs. VTE risk is elevated during
                                     pregnancy and postpartum; this
                                     risk is most pronounced in the
                                     first weeks after delivery,
                                     declining to near baseline levels
                                     by 42 days postpartum. Use of
                                     CHCs, which increases the risk
                                     for VTE in healthy reproductive
                                     age women, might pose an
                                     additional risk if used during
                                     this time. Risk of pregnancy
                                     during the first 21 days
                                     postpartum is very low, but
                                     increases after that point;
                                     ovulation before first menses is
                                     common.

b. 21 to <30 days
   i. With other risk factors        Clarification: For women with
      for VTE (such as age           other risk factors for VTE, these
      [greater than or equal to]     risk factors might increase the
      35 years, previous VTE,        classification to a "4"; for
      thrombophilia, immobility,     example, smoking, deep venous
      transfusion at delivery,       thrombosis/pulmonary embolism,
      BMI [greater than or equal     known thrombogenic mutations, and
      to] 30, postpartum             peripartum cardiomyopathy.
      hemorrhage, postcesarean
      delivery, preeclampsia, or     Evidence: There is no direct
      smoking)                       evidence examining the risk for
  ii. Without other risk             VTE among postpartum women using
      factors for VTE                CHCs. VTE risk is elevated during
                                     pregnancy and postpartum; this
                                     risk is most pronounced in the
                                     first weeks after delivery,
                                     declining to near baseline levels
                                     by 42 days postpartum. Use of
                                     CHCs, which increases the risk
                                     for VTE in healthy reproductive
                                     age women, might pose an
                                     additional risk if used during
                                     this time.

c. 30-42 days
   i. With other risk factors        Clarification: For women with
      for VTE (such as age           other risk factors for VTE, these
      [greater than or equal to]     risk factors might increase the
      35 years, previous VTE,        classification to a "4"; for
      thrombophilia, immobility,     example, smoking, deep venous
      transfusion at delivery,       thrombosis/pulmonary embolism,
      BMI [greater than or equal     known thrombogenic mutations, and
      to] 30, postpartum             peripartum cardiomyopathy.
      hemorrhage, postcesarean
      delivery, preeclampsia, or     Evidence: There is no direct
      smoking)                       evidence examining the risk for
  ii. Without other risk             VTE among postpartum women using
      factors for VTE                CHCs. VTE risk is elevated during
                                     pregnancy and postpartum; this
                                     risk is most pronounced in the
                                     first weeks after delivery,
                                     declining to near baseline levels
                                     by 42 days postpartum. Use of
                                     CHCs, which increases the risk
                                     for VTE in healthy reproductive
                                     age women, might pose an
                                     additional risk if used during
                                     this time.

d. >42 days

Abbreviations: VTE = venous thromboembolism; CHC = combined
hormonal contraceptive; BMI = body mass index (weight [kg] /
height [[m.sup.2]]); COC = combined oral contraceptives.

* Categories: 1 = a condition for which there is no restriction
for the use of the contraceptive method, 2 = a condition for
which the advantages of using the method generally outweigh the
theoretical or proven risks, 3 = a condition for which the
theoretical or proven risks usually outweigh the advantages of
using the method, 4 = a condition that represents an unacceptable
health risk if the contraceptive method is used.

([dagger]) The breastfeeding recommendations are divided by month
in U.S. Medical Eligibility Criteria for Contraceptive Use,
2010.They have been divided by days for purposes of integration
with the postpartum recommendations.

TABLE 3. Summary of recommendations and risk classifications *
for hormonal contraceptive methods and intrauterine devices
during the postpartum period

Condition                              COC/P/R         POP   DMPA

Postpartum
(nonbreastfeeding women)
  a. <21 days                          4                1     1
  b. 21 days to 42 days
     i. With other risk factors        3 ([dagger])     1     1
        for VTE (such as age
        [greater than or equal
        to] 35 years, previous
        VTE, thrombophilia,
        immobility, transfusion at
        delivery, BMI [greater
        than or equal to] 30,
        postpartum hemorrhage,
        postcesarean delivery,
        preeclampsia or smoking)
    ii. Without other risk             2                1     1
        factors for VTE

  c. >42 days                          1                1     1

Postpartum
(breastfeeding women
  ([section]))
  a. <21 days                          4                2     2
  b. 21 to <30 days
     i. With other risk factors        3  ([dagger])    2     2
        for VTE (such as age
        [greater than or equal to]
        35 years, previous VTE,
        thrombophilia, immobility,
        transfusion at delivery,
        BMI [greater than or equal
        to] 30 kg/[m.sup.2],
        postpartum hemorrhage,
        postcesarean delivery,
        preeclampsia or smoking)
    ii. Without other risk             3                2     2
        factors for VTE
  c. 30-42 days
     i. With other risk factors        3  ([dagger])    1     1
        for VTE (such as age
        [greater than or equal to]
        35 years,  previous VTE,
        thrombophilia, immobility,
        transfusion at delivery,
        BMI [greater than or equal
        to] 30, postpartum
        hemorrhage, postcesarean
        delivery, preeclampsia or
        smoking)
     ii. Without other risk            2                1     1
        factors for VTE
  d. >42 days                          2                1     1

Postpartum
(breastfeeding or nonbreastfeeding
women, including postcesarean
delivery)
  a. <10 min after delivery of
      the placenta
  b. 10 min after delivery of the
     placenta to <4 wks
  c. [greater than or equal
     to] 4 wks
  d. Puerperal sepsis

Condition                              Implants   LNG-IUD   Cu-IUD

Postpartum
(nonbreastfeeding women)
  a. <21 days                             1
  b. 21 days to 42 days
     i. With other risk factors           1
        for VTE (such as age
        [greater than or equal
        to] 35 years, previous
        VTE, thrombophilia,
        immobility, transfusion at
        delivery, BMI [greater
        than or equal to] 30,
        postpartum hemorrhage,
        postcesarean delivery,
        preeclampsia or smoking)
    ii. Without other risk                1
        factors for VTE

  c. >42 days                             1

Postpartum
(breastfeeding women
  ([section]))
  a. <21 days                             2
  b. 21 to <30 days
     i. With other risk factors           2
        for VTE (such as age
        [greater than or equal to]
        35 years, previous VTE,
        thrombophilia, immobility,
        transfusion at delivery,
        BMI [greater than or equal
        to] 30 kg/[m.sup.2],
        postpartum hemorrhage,
        postcesarean delivery,
        preeclampsia or smoking)
    ii. Without other risk                2
        factors for VTE
  c. 30-42 days
     i. With other risk factors           1
        for VTE (such as age
        [greater than or equal to]
        35 years,  previous VTE,
        thrombophilia, immobility,
        transfusion at delivery,
        BMI [greater than or equal
        to] 30, postpartum
        hemorrhage, postcesarean
        delivery, preeclampsia or
        smoking)
     ii. Without other risk               1
        factors for VTE
  d. >42 days                             1

Postpartum
(breastfeeding or nonbreastfeeding
women, including postcesarean
delivery)
  a. <10 min after delivery of                       2        1
      the placenta
  b. 10 min after delivery of the                    2        2
     placenta to <4 wks
  c. [greater than or equal                          1        1
     to] 4 wks
  d. Puerperal sepsis                                4        4

Abbreviations: COC = combined oral contraceptives; P = combined
hormonal patch; R = combined vaginal ring; POP = progestin-only
pill; DMPA = depot medroxyprogesterone acetate; IUD = intrauterine
device; LNG-IUD = levonorgestrel-releasing IUD; Cu-IUD =
copper-bearing IUD; VTE = venous thromboembolism; CHC = combined
hormonal contraceptive; BMI = body mass index (weight [kg] / height
[[m.sup.2]]).

* Categories: 1 = a condition for which there is no restriction for
the use of the contraceptive method, 2 = a condition for which the
advantages of using the method generally outweigh the theoretical
or proven risks, 3 = a condition for which the theoretical or
proven risks usually outweigh the advantages of using the method, 4
= a condition that represents an unacceptable health risk if the
contraceptive method is used.

([dagger]) Clarification: For women with other risk factors for
VTE, these risk factors might increase the classification to a "4";
for example, smoking, deep venous thrombosis/ pulmonary embolism,
known thrombogenic mutations, and peripartum cardiomyopathy.

([section]) The breastfeeding recommendations are divided by month
in U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.
They have been divided by days for purposes of integration with the
postpartum recommendations.
COPYRIGHT 2011 U.S. Government Printing Office
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Tepper, Naomi K.; Curtis, Kathryn M.; Jamieson, Denise J.; Marchbanks, Polly A.
Publication:Morbidity and Mortality Weekly Report
Geographic Code:1U5MD
Date:Jul 8, 2011
Words:4003
Previous Article:Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.
Next Article:Vital signs: colorectal cancer screening, incidence, and mortality--United States, 2002-2010.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters